FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2336509748> ?p ?o ?g. }

• W2336509748 endingPage "699" @default.
• W2336509748 startingPage "693" @default.
• W2336509748 abstract "We evaluated the effectiveness of three treatment strategies for the prevention of a first episode of Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus (HIV).In an open-label trial, 843 patients with HIV infection and fewer than 200 CD4+ cells per cubic millimeter received zidovudine plus one of three randomly assigned prophylactic agents, beginning with trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine and followed by a defined sequence of other drugs to be used in cases of intolerance.The estimated 36-month cumulative risks of P. carinii pneumonia were 18 percent, 17 percent, and 21 percent in the trimethoprim-sulfamethoxazole, dapsone, and aerosolized-pentamidine groups, respectively (P = 0.22). The difference in risk among treatment strategies was negligible in patients entering the study with 100 or more CD4+ lymphocytes per cubic millimeter. In those entering with fewer than 100 CD4+ cells per cubic millimeter, the risk was 33 percent with aerosolized pentamidine, as compared with 19 percent with trimethoprim-sulfamethoxazole and 22 percent with dapsone (P = 0.04). The lowest failure rates occurred in patients receiving trimethoprim-sulfamethoxazole, and failures were more common with 50 mg of dapsone than with 100 mg. Toxoplasmosis developed in less than 3 percent of patients. Of the patients assigned to the two systemic therapies, only 23 percent were receiving their assigned drug and dose when they completed the study. The median survival was approximately 39 months in all three groups, and the mortality attributable to P. carinii pneumonia was only 1 percent.In patients with advanced HIV infection, the three treatment strategies we examined have similar effectiveness in preventing P. carinii pneumonia. Strategies that start with trimethoprim-sulfamethoxazole or with high-dose dapsone, rather than aerosolized pentamidine, are superior in patients with fewer than 100 CD4+ lymphocytes per cubic millimeter." @default.
• W2336509748 created "2016-06-24" @default.
• W2336509748 creator A5008749336 @default.
• W2336509748 creator A5017306542 @default.
• W2336509748 creator A5023499969 @default.
• W2336509748 creator A5037592415 @default.
• W2336509748 creator A5055932287 @default.
• W2336509748 creator A5058226785 @default.
• W2336509748 creator A5058502526 @default.
• W2336509748 creator A5070139894 @default.
• W2336509748 creator A5071378911 @default.
• W2336509748 creator A5078089820 @default.
• W2336509748 date "1995-03-16" @default.
• W2336509748 modified "2023-10-17" @default.
• W2336509748 title "A Randomized Trial of Three Antipneumocystis Agents in Patients with Advanced Human Immunodeficiency Virus Infection" @default.
• W2336509748 cites W1963516542 @default.
• W2336509748 cites W1981366475 @default.
• W2336509748 cites W2031048545 @default.
• W2336509748 cites W2050463570 @default.
• W2336509748 cites W2054219948 @default.
• W2336509748 cites W2058393153 @default.
• W2336509748 cites W2073846554 @default.
• W2336509748 cites W2086380193 @default.
• W2336509748 cites W2143294512 @default.
• W2336509748 cites W2326288814 @default.
• W2336509748 cites W2335153389 @default.
• W2336509748 cites W2337303087 @default.
• W2336509748 cites W2338892227 @default.
• W2336509748 cites W2339763729 @default.
• W2336509748 cites W4242604844 @default.
• W2336509748 cites W4244308684 @default.
• W2336509748 cites W4300947860 @default.
• W2336509748 cites W4379136708 @default.
• W2336509748 doi "https://doi.org/10.1056/nejm199503163321101" @default.
• W2336509748 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7854375" @default.
• W2336509748 hasPublicationYear "1995" @default.
• W2336509748 type Work @default.
• W2336509748 sameAs 2336509748 @default.
• W2336509748 citedByCount "298" @default.
• W2336509748 countsByYear W23365097482012 @default.
• W2336509748 countsByYear W23365097482013 @default.
• W2336509748 countsByYear W23365097482014 @default.
• W2336509748 countsByYear W23365097482015 @default.
• W2336509748 countsByYear W23365097482016 @default.
• W2336509748 countsByYear W23365097482017 @default.
• W2336509748 countsByYear W23365097482018 @default.
• W2336509748 countsByYear W23365097482019 @default.
• W2336509748 countsByYear W23365097482020 @default.
• W2336509748 countsByYear W23365097482021 @default.
• W2336509748 countsByYear W23365097482022 @default.
• W2336509748 countsByYear W23365097482023 @default.
• W2336509748 crossrefType "journal-article" @default.
• W2336509748 hasAuthorship W2336509748A5008749336 @default.
• W2336509748 hasAuthorship W2336509748A5017306542 @default.
• W2336509748 hasAuthorship W2336509748A5023499969 @default.
• W2336509748 hasAuthorship W2336509748A5037592415 @default.
• W2336509748 hasAuthorship W2336509748A5055932287 @default.
• W2336509748 hasAuthorship W2336509748A5058226785 @default.
• W2336509748 hasAuthorship W2336509748A5058502526 @default.
• W2336509748 hasAuthorship W2336509748A5070139894 @default.
• W2336509748 hasAuthorship W2336509748A5071378911 @default.
• W2336509748 hasAuthorship W2336509748A5078089820 @default.
• W2336509748 hasBestOaLocation W23365097481 @default.
• W2336509748 hasConcept C126322002 @default.
• W2336509748 hasConcept C141071460 @default.
• W2336509748 hasConcept C203014093 @default.
• W2336509748 hasConcept C2777530519 @default.
• W2336509748 hasConcept C2777559004 @default.
• W2336509748 hasConcept C2777640609 @default.
• W2336509748 hasConcept C2777914695 @default.
• W2336509748 hasConcept C2778048844 @default.
• W2336509748 hasConcept C2778371730 @default.
• W2336509748 hasConcept C2779124865 @default.
• W2336509748 hasConcept C2779196057 @default.
• W2336509748 hasConcept C2779425571 @default.
• W2336509748 hasConcept C2780216070 @default.
• W2336509748 hasConcept C2780727368 @default.
• W2336509748 hasConcept C2780728791 @default.
• W2336509748 hasConcept C2993443204 @default.
• W2336509748 hasConcept C3013748606 @default.
• W2336509748 hasConcept C501593827 @default.
• W2336509748 hasConcept C71924100 @default.
• W2336509748 hasConcept C86803240 @default.
• W2336509748 hasConcept C89423630 @default.
• W2336509748 hasConcept C90924648 @default.
• W2336509748 hasConceptScore W2336509748C126322002 @default.
• W2336509748 hasConceptScore W2336509748C141071460 @default.
• W2336509748 hasConceptScore W2336509748C203014093 @default.
• W2336509748 hasConceptScore W2336509748C2777530519 @default.
• W2336509748 hasConceptScore W2336509748C2777559004 @default.
• W2336509748 hasConceptScore W2336509748C2777640609 @default.
• W2336509748 hasConceptScore W2336509748C2777914695 @default.
• W2336509748 hasConceptScore W2336509748C2778048844 @default.
• W2336509748 hasConceptScore W2336509748C2778371730 @default.
• W2336509748 hasConceptScore W2336509748C2779124865 @default.
• W2336509748 hasConceptScore W2336509748C2779196057 @default.
• W2336509748 hasConceptScore W2336509748C2779425571 @default.
• W2336509748 hasConceptScore W2336509748C2780216070 @default.

• next